Press Release

NATCO Pharma Ltd

Natco House
Road No.2, Banjara Hills
Hyderabad-500 034, India

Hyderabad, India, May 28th, 2025: NATCO Pharma Limited (BSE: 524816 and NSE: NATCOPHARM) ("NATCO") today announced results for fourth quarter of financial year 2025.

NATCO records ₹1,287 Crore consolidated revenue and ₹406 Crore of profit after tax for Q4 FY25 and 4,784 Crore of revenue & 1,883 Crore profit after tax for FY25

NATCO recorded consolidated total revenue of INR 4,784.0 Crore for the year ended on 31st March, 2025, as against INR 4,126.9 Crore for the last year, reflecting a 16% growth. The net profit for the period, on a consolidated basis, was INR 1,883.4 Crore, as against INR 1,388.3 Crore last year showing a growth rate of 36% in its profits.

The company has recorded its highest ever consolidated revenue and profits during this financial year. This is the result of decades of our diligence.

For the fourth quarter (Q4) ended March 31st, 2025, the company recorded a net revenue of INR 1,287.3 Crore, on a consolidated basis, as against INR 1,110.3 Crore during Q4, FY 2024. The profit for the fourth quarter, on a consolidated basis, was INR 406.0 Crore, as against INR 386.3 Crore same period last year.

During the quarter, the Company took an impairment charge of INR 50 crore in the Crop Health Science business related to Property, Plant and Machinery, a chargeback adjustment of approximately INR 25 crore in its US subsidiary apart from higher R&D expenses.

As of 31st March 2025, company had a strong cash position of over INR 3,000 crore as it prepares for headwinds coming from its US business during the financial year 2025-26. The Company estimates a possible dip in revenue by 20% and profits by 30% due to geopolitical uncertainties & pricing pressure in its core product portfolio in the US and increased R&D expenses.

Segmental Revenue Split (INR Cr)

Segment	Q4FY25	FY25
Active Pharmaceutical Ingredients (API)	46.4	201.8
Domestic Formulations	99.4	400.0
Formulations export (Incl. profit share and subs)	1,052.5	3,759.7
Other operating and non-operating income	74.0	362.7
Crop Health Sciences (CHS)	15.0	59.8
Total	**1,287.3**	**4,784.0**

NATCO Pharma Ltd

Natco House
Road No.2, Banjara Hills
Hyderabad-500 034, India

About NATCO Pharma Limited

NATCO Pharma Limited (www.natcopharma.com), (NSE:NATCOPHARM, BSE: 524816, Reuters: NATP.NS, Bloomberg: NTCPH,) headquartered at Hyderabad, India, develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharma ingredients and crop protection products. The Company is a R&D oriented, and a science driven, leading Oncology player in the targeted therapies of domestic market and focuses on limited competition molecule in the US. The Company's manufacturing facilities are approved by several leading regulatory authorities like US FDA, Brazil ANVISA, Health Canada, WHO and others catering to 50+ global markets. For more information, please visit us at www.natcopharma.com or click on LinkedIn or X (formerly Twitter)

For further information please contact:

Rajeev Menon, Investor Relations

r.menon@natcopharma.co.in/investors@natcopharma.co.in

Rajesh Chebiyam, EVP - CHS

rajesh.chebiyam@natcopharma.co.in

Earnings Call Details:

- *Date: 29th May 2025*
- *Time: 11 AM IST*
- *Dial-in-Numbers: (+91 22) 62801222 / 71158123*
- *Pre-register using the link: https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=9808365&linkSecurityString=46d41de81b*